Cathay Taiex Daily 2x ETF logo

Cathay Taiex Daily 2x ETF (00663L)

Market Closed
12 Aug, 05:30
TWSE TWSE
NT$
101. 80
+1.6
+1.5968%
NT$
- Market Cap
- Div Yield
5.22M Volume
NT$ 100.2
Previous Close
Add Transaction
Day Range
100.5 102.2
Year Range
32.14 121.25
Want to track 00663L and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

00663L closed today higher at NT$101.8, an increase of 1.5968% from yesterday's close, completing a monthly decrease of -12.1278% or -NT$14.05. Over the past 12 months, 00663L stock gained 113.0599%.
00663L is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.

00663L Chart

Cathay Taiex Daily 2x ETF (00663L) FAQ

What is the stock price today?

The current price is NT$101.80.

On which exchange is it traded?

Cathay Taiex Daily 2x ETF is listed on TWSE.

What is its stock symbol?

The ticker symbol is 00663L.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Cathay Taiex Daily 2x ETF ever had a stock split?

No, there has never been a stock split.

Cathay Taiex Daily 2x ETF Profile

TWSE Exchange
Taiwan Country

Overview

Stayble Therapeutics AB (publ) is a pioneering biotech company based in Gothenburg, Sweden, focusing on developing innovative treatments for chronic pain due to disc degeneration. Since its inception in 2015, the company has been at the forefront of addressing chronic low back and leg pain through cutting-edge medical solutions. Leveraging advanced research and development capabilities, Stayble Therapeutics AB (publ) aims to improve the quality of life for patients suffering from debilitating chronic pain conditions by introducing non-surgical, injectable treatments.

Products and Services

STA363

Stayble Therapeutics AB (publ) is dedicated to the development of STA363, a revolutionary injectable treatment designed specifically for chronic pain caused by disc degeneration. STA363 targets the core of the issue by being directly injected into the affected disc, providing a potentially long-lasting solution to individuals experiencing chronic low back and leg pain. This approach not only aims to alleviate pain but also to contribute to the field of pain management by offering an innovative, non-surgical alternative for patients.

Contact Information

Address: Lennart Torstenssonsgatan 6, Gothenburg, Sweden, 412 56
Phone: (02)2700-8399